BIO AMOVIR is a company of the SAMFI-INVEST
Group SAS with a capital of 57 800 000 euros,
investment company of the Samson family, based
in Caen, Normandy.
The SAMFI-INVEST group, from its historical
activity, services to companies, has chosen to
diversify in fields where it can occupy positions of
challengers compared to the Leaders present on
In order to conduct research on innovative therapies against enveloped
viruses, BIO AMOVIR relies on a multidisciplinary team as well as on
partnerships with teams of excellence from university or private
Laboratories recognized by the health authorities have conducted the
biological safety studies.
BIO AMOVIR is a biotechnology company specialized in research and
development in the field of virology. Targeting enveloped viruses in
particular, it develops drug candidates to effectively treat several viral
infections such as herpes, influenza or even AIDS and hepatitis and today
Covid-19. When it was founded in 2015, BIO AMOVIR built on its team's
previous studies highlighting the possibility of targeting these viruses with
a totally innovative approach.
Some of the results obtained led to the development of an effective
medical device for the prevention of herpes.
A commercial activity in the field of health products was subsequently
developed, allowing the company to acquire financial independence in
order to carry out research and development work.
The diversity of its activities allows it to ensure a better spread of risks.
- Transport, through its majority shareholding in the MALHERBE Group, the third largest French forwarding agent;
- Self-storage, through its subsidiary LOCABOX.
- Industries and raw materials
- Digital advertising
- Green energy
- Real estate